@conference{d0fdf3794c03462590932f0fb80bc103,
title = "Integrated Clinical Experience with ONC201 in H3 K27M Glioma",
author = "Yazmin Odia",
note = "2059 Background: ONC201 is a DRD2 antagonist in Phase II trials for cancers that exhibit dysregulation of the dopamine pathway. We previously reported an objective response in the first recurrent H3 K27M midline glioma patient who received ONC201 and that H3 K27M gliomas exhibit enhanced sensitivity to the compound in vitro.; ASCO 2018 ; Conference date: 01-01-2018",
year = "2018",
language = "American English",
}